Compare DiaKine Therapeutics vs Nuon Therapeutics

Nuon Therapeutics

Unclaimed

Nuon Therapeutics is 22 yrs old and is based in United States.

Nuon Therapeutics discovers novel uses for marketed drugs. The advantage of this approach is that the development program for the marketed indication will have investigated the compounds toxicity and established its tolerability. This makes it possible to proceed directly to clinical trials once the efficacy of the compound has been established in animal models. The costs and risks involved in the drug development process are greatly reduced. Tranilast is under development for the treatment of patients with multiple sclerosis. The only drugs available for the treatment of patients with relapsing-remitting and secondary- progressive multiple sclerosis are interferon-beta, glatiramer acetate and mitoxantrone which reduce the number of relapses and the rate of disease progression. Tysabri is a monoclonal antibody for the treatment of patients with relapsing forms of multiple sclerosis. There is an urgent need for new therapies which can be orally administered and are more cost effective. Tranilast inhibits antigen-specific T cell proliferation, skews a TH1-type T cell response to TH2 and suppresses the activation of antigen presenting cells by interfering with signal transducer and activator of transcription (STAT) pathways. The oral administration of Tranilast reverses paralysis in mice with established experimental autoimmune encephalomyelitis.